Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme

Ramcharan Singh Angom, Sujan Kumar Mondal, Fei Wang, Vijay Sagar Madamsetty, Enfeng Wang, Shamit K. Dutta, Yash Gulani, Rachel Sarabia-Estrada, Jann N. Sarkaria, Alfredo Quiñones-Hinojosa, Debabrata Mukhopadhyay

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Glioblastoma multiforme (GBM) is a highly proliferative and locally invasive cancer with poor prognosis and a high recurrence rate. Although anti-VEGF (vascular endothelial growth factor) therapy offers short-term benefit to GBM patients, this approach fails as the tumor develops into a more invasive and drug-resistant phenotype and ultimately recurs. Recently, both glioma stemlike cells (GSCs) and brain tumor–initiating cells (BTICs) have been implicated in GBM recurrence and its resistance to therapy. We observed that patient-derived GBM cells expressing shRNAs of VEGF or neuropilin-1 (NRP-1) attenuate cancer stem cell markers, inhibit the tumor-initiating cell’s neurosphere-forming capacity, and migration. Furthermore, both VEGF and NRP-1 knockdown inhibit the growth of patient-derived GBM xenografts in both zebrafish and mouse models. Interestingly, NRP-1–depleted patient-derived GBM xenografts substantially prolonged survival in mice compared to that of VEGF depletion. Our results also demonstrate that NRP-1 ablation of patient-derived GBM cells improves the sensitivity of TMZ and enhances the overall survival of the respective tumor-bearing mice. This improved outcome may provide insight into the inhibition of GBM progression and effective treatment strategies by targeting NRP-1 in addition to chemotherapy and radiotherapy.

Original languageEnglish (US)
Pages (from-to)7114-7126
Number of pages13
Issue number48
StatePublished - Nov 26 2020

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research


Dive into the research topics of 'Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this